|More than 90,000 patients in Viet Nam are hospitalised due to dengue fever every year, and 87 of them die of the disease. — VNA Photo
HCM CITY (VNS) — A clinical study of a new dengue vaccine in five countries in Asia, including Viet Nam, shows overall efficacy of 56.5 per cent against symptomatic dengue in children aged two to 14.
The results of the landmark phase III dengue vaccine study also showed an 88.5 per cent reduction of dengue haemorrhagic fever, the severe form of dengue, according to the WHO criteria.
Asso. Prof, Dr Tran Ngoc Huu, main researcher of the vaccine in Viet Nam, spoke on Monday at a workshop about the study's results.
The study, conducted in Thailand, the Philippines, Indonesia, Malaysia and Viet Nam, of 10,275 children aged between 2 and 14, reduced the risk of hospitalization due to dengue fever by 67 per cent, Huu said.
The vaccine, developed by Sanofi Pasteur, has efficacy against all four dengue strains.
The study was a randomized, observer-blind, placebo-controlled multi-centre trial.
In the study's clinical trial in Viet Nam beginning in 2011, 2,336 children in An Giang Province's Long Xuyen City and Tien Giang Province's My Tho City in the Mekong Delta were given three shots at six-month intervals.
The favorable vaccine safety profile observed during 25 months of follow-up during the phase III of the study in the five Asian countries was consistent with the safety profile documented in phases I, II and IIb, he said.
The vaccinated children will continue to be monitored for safety reasons until 2017.
Each year, 100 million patients with dengue fever were reported to be infected with dengue fever. Of that number, 500,000 are hospitalised due to dengue haemorrhagic fever.
According to Dr Tran Dac Phu, head of HCM City's Preventive Health Department, more than 90,000 patients in Viet Nam are hospitalised due to dengue fever every year, and 87 of them die of the disease.
Phan Trong Lan, head of the HCM City Pasteur Institute, said the efficacy of the vaccine against the D2 dengue strain was only 35 per cent. More research on this strain as well as vaccines for infants under two years old was needed, he said. — VNS